益心舒胶囊治疗2型糖尿病合并冠心病心绞痛的临床疗效分析

摘要

目的:探讨益心舒胶囊对2型糖尿病合并冠心病心绞痛患者的临床疗效.方法:选取河北省张家口市第一医院内分泌科收治的2型糖尿病合并冠心病心绞痛患者88例,随机分为对照组与观察组,每组44例.对照组给予常规降糖及抗心绞痛药治疗,观察组在其基础上联合益心舒胶囊治疗,2组均治疗8周.治疗后统计2组临床疗效;检测并比较治疗前后2组患者血糖、血脂水平及血小板活化指标水平的变化.结果:与对照组比较,治疗后观察组临床症状改善及心电图改善显效比例及总有效率均显著升高,无效比例显著降低,差异有统计学意义(P ＜0.05或P＜0.01);与治疗前比较,治疗后2组FBG、2 h PBG、HbA1c及TG、TC、LDL-C水平均明显降低,且观察组显著低于对照组,差异有统计学意义(P＜0.05或P＜0.01),而2组HDL-C水平明显升高,且观察组显著高于对照组(P＜0.01);与治疗前比较,治疗后对照组仅PAC-1及MAR降低(P＜0.05),而观察组LAP、CD62P、PAC-1及MAR降低,且明显低于对照组,差异有统计学意义(P＜0.01).结论:益心舒胶囊可显著改善2型糖尿病合并冠心病心绞痛患者的血糖、血脂水平,明显抑制血小板活化,提高临床疗效.%Objective:To observe the clinical efficacy of Yixinshu capsule in the treatment of diabetes Ⅱ mellitus combined with coronary heart disease angina pectoris.Methods:A total of 88 cases patients with diabetes Ⅱ mellitus and coronary heart disease angina pectoris were elected and divided randomly into control group (n =44) and observation group (n =44).The control group were treated with routine hypoglycemic and antianinal drugs and the observation group were treated with Yixinshu capsule on the basis of the control.Both groups were treated for 8 weeks.Analyze clinical efficacy of the two groups after treatment and detecte and compare the changes of blood glucose,blood fat and platelet activation indexes before and after treatment.Results:After treatment,clinical symptoms and electrocardiogram excellent ratio and effective rate increased significantly,and null cases ratio decreased (P ＜ 0.05 or P ＜ 0.01).After treatment,the levels of serum FBG,2 h PBG,HbA1 c and TG,TC,LDL-C of two groups decreased significantly,and those of the the observation group decreased more greatly than the control group (P ＜0.05 or P ＜0.01).Besides,the levels of HDL-C in the two groups increased,and that of the observation group was higher than that of the control group (P ＜ 0.01).After treatment,levels of PAC-1 and MAR of control group decreased (P ＜ 0.05) as well as LAP,CD62P,PAC-1 and MAR which were lower than that of the control group (P ＜ 0.01).Conclusion:Yixinshu capsule can decrease blood glucose,and blood fat of patients with diabetesⅡ mellitus and coronary heart disease angina pectoris,plus inhibiting platelet activation and enhancing clinical efficacy.